Algorithms to Diagnose Pulmonary Arterial Hypertension

Shanghai Jiao Tong University

Status: Unknown

Conditions: Pulmonary Arterial Hypertension

Treatments: Other: calculated radscore

Study type: Observational

Funder types: Other

Identifiers

NCT05417373

diagnosis of PAH

Details and patient eligibility

About

The investigators intend to evalute the value of radiomics signature of pulmonary vessels from chest computed tomography (CT) for dianosis and prognosis of pulmonary arterial hypertension.

Full description

Pulmonary arterial hypertension (PAH) is a heterogeneous disorder composed of varying pathobiology that may involve multiple clinical conditions. Computed tomography (CT) is a minimally invasive imaging technique capable of providing both high contrast and high resolution detail of the lungs and arteries. Application of radiomics as prognosis and diagnosis tools could quantifies high-dimensional features from CT data to investigate vescualr heterogeneity.Development and validation of PAH diagnosis Algorithms based on radiomics may serve as a complementary readout to current CT-based metrics and provide valuable evidence to make the treatment management decision in early PAH.

Enrollment: 250 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Chest CT examination and cardiac ultrasound examination were performed within 3 months before and after right heart catheterization;
2. mPAP > 25mmHg and PVR< 3woods (measured by right heart catheter) and pulmonary vascular resistance was collected as PAH group whereas Healthy Volunteers as non-PAH control group in developement corhort;
3. sPAP > 36mmHg (measured by echocardiography) was collected in validation corhort.

Exclusion criteria

1.Cancer; 2. The quality of chest CT and cardiac ultrasound images is poor; 3.Pulmonary vascular segmentation is affected by thoracic organ displacement or pulmonary vascular complete occlusion due to diseases ,such as spinal deformity.

Trial design

250 participants in 2 patient groups

The development cohort

Description:

The development cohort was composed of patients diagnosed with PAH and healthy control group from 2019.1-2021.5 in RenjiH.

The validation cohort

Description:

The validation cohort was composed of patients are suspected as PAH by echocardiography in 2021.5-2021.12 or suspected patients are form other medical institutions.

Treatment:

Other: calculated radscore